GCP
VIRX

GSA Capital Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

GSA Capital Partners’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,184
Closed -$182K – 1565
2020
Q4 		$182K Buy
26,184
+16,825
+180% +$87.8K 0.03% 1018
2020
Q3 		$41K Buy
+9,359
New +$81.8K 0.01% 1193

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GSA Capital Partners's VIRX Position: Q1 2021 in Review

GSA Capital Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2021, closing a stake of 26,184 shares — an estimated $182K sold.

GSA Capital Partners first reported a position in VIRX in Q3 2020 and held it in 2 quarters. The position peaked at $182K in Q4 2020. 50 funds tracked by Wall St. Rank hold VIRX as of Q1 2021.

  • GSA Capital Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • GSA Capital Partners sold 26,184 Viracta Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $182K.
  • GSA Capital Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • GSA Capital Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $182K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.